ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020
The validation of the Italian version of the COmprehensive Score for financial Toxicity (COST).
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments.PharmacoEconomics - open · 2025Pooled it
- Measures of financial toxicity in cancer survivors: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- Guideline
- Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review.BMJ open · 2022Pooled it
- Financial Toxicity in Women with Endometriosis: Psychometric Validation of the Polish COST-FACIT with Analysis of Demographic and Clinical Factors.Healthcare (Basel, Switzerland) · 2026Article
- Financial toxicity on treatment outcomes in head & neck cancer patients undergoing radiation therapy.Radiation oncology (London, England) · 2025Article
- The financial toll of cancer: uncovering the links between financial toxicity and symptom burden.The oncologist · 2025Observational
- Cross-Cultural Validation of the COmprehensive Score for Financial Toxicity (COST) Measure in an Australian Sample.Cancer medicine · 2025Article
- Validity, test-retest reliability, and responsiveness of the Indonesian version of FACIT-COST measure for subjective financial toxicity.Health and quality of life outcomes · 2024Article
- Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy.The American journal of hospice & palliative care · 2024Review
- Assessing suffering of patients on cancer treatment and of those no longer treated using ESAS-Total Care (TC).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Financial toxicity of patients with lung cancer in China: Results from a National Survey Study.Cancer medicine · 2023Article
- The development and validation of a patient-reported outcome measure to assess financial hardship among older cancer survivors in China: hardship and recovery with distress survey.Frontiers in oncology · 2023Article
- Financial toxicity in female patients with breast cancer: a national cross-sectional study in China.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Assessment of self-reported financial toxicity among patients with nasopharyngeal carcinoma undergoing radiotherapy: A cross-sectional study in western China.Frontiers in oncology · 2022Article
- Predictors of financial toxicity and its associations with health-related quality of life and treatment non-adherence in Turkish cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Identifying a cut-off score for the COST measure to indicate high financial toxicity and low quality of life among cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.JACC. CardioOncology · 2021Article
- Translation and validation of the Traditional Chinese version of the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (Version 2).Health and quality of life outcomes · 2021Article
- Assessing the reliability and validity of comprehensive score for financial toxicity (COST) among radiation oncology patients in India: a cross-sectional pilot study.Ecancermedicalscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFinancial toxicity (FT) is the unintended, potential economic harm or damage of oncologic treatments that has become a medical problem with political implications. To assess FT, the COmprehensive Score for financial Toxicity (COST) questionnaire was developed. Since an Italian version is not available yet, we aimed to validate the Italian version of the COST questionnaire in a population of cancer patients during oncologic treatments or follow-up.
methodsA sample of Italian native outpatients were asked to fill the Italian version of the COST and five other self-administered questionnaires to assess quality of life, treatment-related symptoms, hope, distress, and unmet needs. Additionally, a subsample of patients was asked to retake the COST after 2-6 weeks.
resultsA single factor better represents the scale structure. Internal consistency and test-retest reliability were good. Evidence of convergent and discriminant validity was provided and criterion validity was established, showing that financial toxicity predicts the patient's distress. Finally, known-groups validity was confirmed, testing the differences related to treatment-related expenses, sociodemographic characteristics, stage of the disease, and performance status.
conclusionThe current findings suggest the Italian version of the COST is a psychometrically sound scale that potentially offers an added value in assessing FT in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.